Nosocomial infections caused by Pseudomonas aeruginosa in cancer clinics

Автор: Dmitrieva Natalia V., Eidelshtein Mikhail V., Aginova Viktoria V., Perukhova Irina N., Grigorievskaya Zlata V., Bagirova Natalia S., Tereshchenko Inna V., Kulaga Elena V., Klyuchnikova Irina A., Sokolova Elena N., Shek Evgeny A., Skleenova Elena Yu.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Клинические исследования

Статья в выпуске: 2 т.18, 2019 года.

Бесплатный доступ

The purpose of the study was to evaluate the frequency of isolation of multi-resistant Pseudomonas aeruginosa and identify the mechanisms of resistance to carbapenems. material and methods. We analyzed 866 strains of Pseudomonos aeruginosa isolated from clinical samples from cancer patients in the period 2014-2016. the level of resistance to piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, amikacin in dynamics was determined. carbapenem-resistant (car-R) strains were examined for the presence of enzymes. Results. Between 2014 and 2016, the number of strains resistant to piperacillin/tazobactam was 20.1-12.9 %, to ceftazidime - 33.0-32.9 %, to cefepime - 25.6-32.9 %, ciprofloxacin - 36.8-43.8 %, amikacin - 23.8-24.9 %. No statistically significant differences were found (p>0.05). However, an increase in the number of car-R strains from 31.7 to 43.8 % was observed (p

Еще

Pseudomonas aeruginosa, vim, ges, cancer patients, carbapenemase products, nosocomial infections, antibacterial drugs

Короткий адрес: https://sciup.org/140254249

IDR: 140254249   |   DOI: 10.21294/1814-4861-2019-18-2-28-34

Статья научная